3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
29
Meningioma
5
Gastro-enteropancreatic neuroendocrine tumor
5
Paraganglioma
4
Carcinoma, Neuroendocrine
4
Pheochromocytoma
3
Neuroblastoma
3
Neoplasms, Germ Cell and Embryonal
2
Neoplasms
2
Medulloblastoma
2
Glioma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Carcinoma, Medullary
2
Carcinoid Tumor
2
Adenoma, Islet Cell
2
Stomach Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Serotonin Syndrome
1
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Osteosarcoma
1
Neuroectodermal Tumors
1
Neoplasms, Nerve Tissue
1
Interventions
Cyclophosphamide
10
fludarabine
5
Radiotherapy
5
Doxorubicin
5
Gemcitabine
3
sargramostim
2
fludarabine phosphate
2
aldesleukin
2
Sunitinib
2
Radiation Dose Hypofractionation
2
Nivolumab
2
Leukapheresis
2
Ifosfamide
2
Docetaxel
2
Decitabine
2
Dacarbazine
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
trofosfamide
1
tremelimumab
1
temsirolimus
1
sotigalimab
1
ribociclib
1
poly ICLC
1
pembrolizumab
1
pegfilgrastim
1
pazopanib
1
pasireotide
1
olaparib
1
lutetium Lu 177 dotatate
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Sarcoma, Synovial
×
lutetium Lu 177 dotatate
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled